Yamaguchi, Hiromi <br/><br/>
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.  [electronic resource] 

 -  Endocrine journal  Feb 2020 
 - 201-210 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1348-4540 
<br/><br/><label>Standard No.: </label>10.1507/endocrj.EJ19-0266  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acromegaly--drug therapy<br/>Adenoma--complications<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Bromocriptine--therapeutic use<br/>Cabergoline--therapeutic use<br/>Chemical and Drug Induced Liver Injury--epidemiology<br/>Child<br/>Disease Progression<br/>Dopamine Agonists--therapeutic use<br/>Drug Therapy, Combination<br/>Female<br/>Growth Hormone-Secreting Pituitary Adenoma--complications<br/>Human Growth Hormone--analogs & derivatives<br/>Humans<br/>Hypoglycemia--chemically induced<br/>Insulin-Like Growth Factor I--metabolism<br/>Japan--epidemiology<br/>Male<br/>Middle Aged<br/>Neurosurgical Procedures<br/>Octreotide--therapeutic use<br/>Peptides, Cyclic--therapeutic use<br/>Product Surveillance, Postmarketing<br/>Radiotherapy<br/>Receptors, Somatotropin--antagonists & inhibitors<br/>Somatostatin--analogs & derivatives<br/>Tumor Burden<br/>Young Adult